Femasys (NASDAQ:FEMY) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Femasys (NASDAQ:FEMY) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $12.00 price target on the stock.

Separately, Chardan Capital lowered their price objective on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Femasys Stock Up 7.7 %

Shares of FEMY opened at $1.12 on Wednesday. The business’s 50 day simple moving average is $1.14 and its 200-day simple moving average is $1.12. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. The company has a market capitalization of $25.65 million, a P/E ratio of -1.38 and a beta of -2.83. Femasys has a one year low of $0.73 and a one year high of $2.40.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The company had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.40 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%. As a group, sell-side analysts predict that Femasys will post -0.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Femasys

Several institutional investors and hedge funds have recently made changes to their positions in FEMY. CM Management LLC increased its position in shares of Femasys by 6.3% during the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after acquiring an additional 25,000 shares in the last quarter. Aljian Capital Management LLC bought a new position in Femasys during the third quarter worth about $27,000. XTX Topco Ltd increased its holdings in shares of Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after acquiring an additional 18,004 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Femasys by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after acquiring an additional 17,473 shares during the period. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.